TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)
14.50
+0.55 (3.94%)
Sep 10, 2024, 1:30 PM CST
TaiGen Biopharmaceuticals Holdings Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 195.2 | 374.66 | 243.11 | 364.93 | 60.85 | 136.26 | Upgrade
|
Short-Term Investments | 583.48 | 598.2 | 591.11 | 495.38 | 197.22 | 434.77 | Upgrade
|
Trading Asset Securities | 324.04 | 65.14 | 64.39 | 64.09 | 72.7 | 66.51 | Upgrade
|
Cash & Short-Term Investments | 1,103 | 1,038 | 898.6 | 924.4 | 330.78 | 637.54 | Upgrade
|
Cash Growth | 27.33% | 15.51% | -2.79% | 179.46% | -48.12% | -18.51% | Upgrade
|
Accounts Receivable | 10.01 | 8.98 | 18.41 | 278.28 | 7.31 | 1.77 | Upgrade
|
Other Receivables | 10.87 | 24.88 | 5.3 | 2.61 | 28.64 | 33.49 | Upgrade
|
Receivables | 20.87 | 33.87 | 23.71 | 280.89 | 35.95 | 35.26 | Upgrade
|
Inventory | 49.02 | 34.15 | 15.35 | 17.88 | 14.65 | 7.52 | Upgrade
|
Other Current Assets | 7 | 4.37 | 11.57 | 8.84 | 10.22 | 23.5 | Upgrade
|
Total Current Assets | 1,180 | 1,110 | 949.24 | 1,232 | 391.6 | 703.82 | Upgrade
|
Property, Plant & Equipment | 78.56 | 90.61 | 56.6 | 80.43 | 42.47 | 64.83 | Upgrade
|
Long-Term Investments | 6.64 | 9.71 | 23.98 | 53.9 | 85.86 | 133.82 | Upgrade
|
Other Intangible Assets | 13.37 | 0.1 | 0.23 | 0.16 | 0.29 | 0.68 | Upgrade
|
Other Long-Term Assets | 6.22 | 19.04 | 16.96 | 26.31 | 36.24 | 42.95 | Upgrade
|
Total Assets | 1,284 | 1,230 | 1,047 | 1,393 | 556.45 | 946.11 | Upgrade
|
Short-Term Debt | - | - | 3 | - | - | 30 | Upgrade
|
Current Portion of Leases | 16.15 | 15.98 | 18.34 | 17.99 | 17.12 | 19.07 | Upgrade
|
Current Income Taxes Payable | - | - | 3.07 | 27.86 | - | 5.29 | Upgrade
|
Current Unearned Revenue | 0.15 | 0.15 | 0.15 | 0.18 | 44.41 | 0.18 | Upgrade
|
Other Current Liabilities | 41.69 | 31.76 | 26.76 | 43.85 | 33.37 | 34.78 | Upgrade
|
Total Current Liabilities | 57.99 | 47.89 | 51.32 | 89.88 | 94.91 | 89.31 | Upgrade
|
Long-Term Leases | 50.59 | 58.71 | 17.13 | 35.47 | - | 17.12 | Upgrade
|
Long-Term Unearned Revenue | 0.25 | 0.33 | 0.48 | 0.62 | 0.79 | 0.97 | Upgrade
|
Total Liabilities | 112.74 | 110.94 | 76.98 | 139.11 | 114.26 | 130.92 | Upgrade
|
Common Stock | 20.94 | 20.94 | 20.91 | 20.91 | 20.91 | 20.91 | Upgrade
|
Additional Paid-In Capital | 454.44 | 444.61 | 450.26 | 455.25 | 675.14 | 660.68 | Upgrade
|
Retained Earnings | 736.73 | 678.68 | 542.05 | 778.3 | -300.21 | 103.96 | Upgrade
|
Comprensive Income & Other | -40.45 | -25.34 | -43.2 | -0.77 | 46.34 | 29.64 | Upgrade
|
Shareholders' Equity | 1,172 | 1,119 | 970.03 | 1,254 | 442.18 | 815.18 | Upgrade
|
Total Liabilities & Equity | 1,284 | 1,230 | 1,047 | 1,393 | 556.45 | 946.11 | Upgrade
|
Total Debt | 66.74 | 74.69 | 38.47 | 53.46 | 17.12 | 66.19 | Upgrade
|
Net Cash (Debt) | 1,036 | 963.3 | 860.13 | 870.94 | 313.66 | 571.35 | Upgrade
|
Net Cash Growth | 32.23% | 12.00% | -1.24% | 177.67% | -45.10% | -26.97% | Upgrade
|
Net Cash Per Share | 1.39 | 1.34 | 1.20 | 1.21 | 0.44 | 0.80 | Upgrade
|
Filing Date Shares Outstanding | 713.43 | 717.84 | 716.84 | 716.84 | 716.84 | 716.84 | Upgrade
|
Total Common Shares Outstanding | 713.43 | 717.84 | 716.84 | 716.84 | 716.84 | 716.84 | Upgrade
|
Working Capital | 1,122 | 1,062 | 897.92 | 1,142 | 296.69 | 614.51 | Upgrade
|
Book Value Per Share | 1.64 | 1.56 | 1.35 | 1.75 | 0.62 | 1.14 | Upgrade
|
Tangible Book Value | 1,158 | 1,119 | 969.8 | 1,254 | 441.89 | 814.5 | Upgrade
|
Tangible Book Value Per Share | 1.62 | 1.56 | 1.35 | 1.75 | 0.62 | 1.14 | Upgrade
|
Machinery | - | 143.76 | 143.76 | 140.92 | 148.2 | 153.31 | Upgrade
|
Leasehold Improvements | - | 60.71 | 60.71 | 60.67 | 58.11 | 58.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.